Unleashing precision: A review of targeted approaches in pleural mesothelioma
-
Published:2024-11
Issue:
Volume:203
Page:104481
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Occhipinti Mario, Brambilla MartaORCID, Di Liello Raimondo, Ambrosini Paolo, Lobianco Lorenzo, Leporati Rita, Salvarezza Maria, Vitiello Fabiana, Marchesi Silvia, Manglaviti Sara, Beninato Teresa, Mazzeo Laura, Proto Claudia, Prelaj Arsela, Ferrara Roberto, Della Corte Carminia Maria, Lo Russo Giuseppe, de Braud Filippo, Ganzinelli Monica, Viscardi Giuseppe
Funder
Ministry of Health
Reference157 articles.
1. Treatment of ovarian cancer cell lines with 5-aza-2’-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules;Adair;Cancer Immunol. Immunother.,2009 2. Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with Afatinib;Agatsuma;J. Thorac. Oncol.,2017 3. Efficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancers;Alewine;Mol. Cancer Ther.,2014 4. E. Aliagas, A. Alay, M. Martínez-Iniesta, M. Hernández-Madrigal, D. Cordero, M. Gausachs, E. Pros, M. Saigí, S. Busacca, A.J. Sharkley, A. Dawson, R. Palmero, S. Padrones, S. Aso, I. Escobar, R. Ramos, R. Llatjós, A. Vidal, M. Varela, M. Sánchez-Céspedes, D. Fennell, C. Muñoz-Pinedo, A. Villanueva, X. Solé, E. Nadal, Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma, BioRxiv (2021) 2021.02.08.430196. 〈https://doi.org/10.1101/2021.02.08.430196〉. 5. Anon, APG-2449 in Patients With Advanced Solid Tumors - Full Text View - ClinicalTrials.gov, (n.d.). 〈https://clinicaltrials.gov/ct2/show/NCT03917043〉 (accessed December 11, 2022).
|
|